Head to Head Survey: OnKure Therapeutics (OKUR) vs. Its Rivals

OnKure Therapeutics (NASDAQ:OKUR) is one of 1,047 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare OnKure Therapeutics to related companies based on the strength of its risk, institutional ownership, valuation, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of current recommendations for OnKure Therapeutics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	0	0	2	1	3.33
OnKure Therapeutics Competitors	7593	20858	48469	1190	2.55

OnKure Therapeutics presently has a consensus target price of $37.50, indicating a potential upside of 134.52%. As a group, “Pharmaceutical preparations” companies have a potential upside of 72.35%. Given OnKure Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe OnKure Therapeutics is more favorable than its competitors.

Volatility & Risk

OnKure Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, OnKure Therapeutics’ competitors have a beta of 1.05, suggesting that their average share price is 5% more volatile than the S&P 500.

Profitability

This table compares OnKure Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-51.17%	-47.11%
OnKure Therapeutics Competitors	-3,620.42%	-274.40%	-33.57%

Insider and Institutional Ownership

91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 17.9% of OnKure Therapeutics shares are held by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares OnKure Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OnKure Therapeutics	N/A	-$77.39 million	-1.31
OnKure Therapeutics Competitors	$1.70 billion	$155.46 million	-5.59

OnKure Therapeutics’ competitors have higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

OnKure Therapeutics beats its competitors on 9 of the 13 factors compared.

About OnKure Therapeutics

Reneo Pharmaceuticals Inc.is a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Inc.is based in SAN DIEGO.